Izrael - angielski - Ministry of Health

abbvie biopharmaceuticals ltd, israel - ritonavir - film coated tablets - ritonavir 100 mg - ritonavir - ritonavir - is indicated alone or in combination with other antiretroviral agents for the treatment of patients with hiv infection when therapy is warranted based on clinical and/or immunological evidence of disease progression

Izrael - angielski - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol 2 mcg - capsules - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.

Izrael - angielski - Ministry of Health

abbvie biopharmaceuticals ltd, israel - paricalcitol 4 mcg - capsules - paricalcitol - zemplar is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal insufficiency (chronic kidney disease stage 3 and 4 ) patients and chronic renal failure (chronic kidney disease stage 5) patients on haemodialysis or peritoneal dialysis.

Izrael - angielski - Ministry of Health

abbvie biopharmaceuticals ltd, israel - ritonavir 100 mg - capsules - ritonavir - is indicated alone or in combination with other antiretroviral agents for the treatment of patients with hiv infection when therapy is warranted based on clinical and/or immunological evidence of disease progression.

Izrael - angielski - Ministry of Health

abbvie biopharmaceuticals ltd, israel - ritonavir 100 mg - capsules - ritonavir - is indicated alone or in combination with other antiretroviral agents for the treatment of patients with hiv infection when therapy is warranted based on clinical and/or immunological evidence of disease progression.

Izrael - angielski - Ministry of Health

abbvie biopharmaceuticals ltd, israel - palivizumab 100 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.

Izrael - angielski - Ministry of Health

abbvie biopharmaceuticals ltd, israel - palivizumab 50 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.

Izrael - angielski - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - pen - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r

Izrael - angielski - Ministry of Health

abbvie biopharmaceuticals ltd, israel - isoflurane 99.9 % - solution for inhalation - isoflurane - for general anaesthesia.

Izrael - angielski - Ministry of Health

abbvie biopharmaceuticals ltd, israel - adalimumab 40 mg / 0.8 ml - solution for injection - pfs - adalimumab - * rheumatoid arthritis: humira in combination with methotrexate is indicated for: - the treatment of moderate to severe active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. - the treatment of severe active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. humira can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. humira has been shown to reduce the rate of progression of joint damage as measured by x-ray adn to impove physical function when given in combination with methotrexate. * crohn's disease : humira is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active crohn's disease who have had an inadequate response to conventional therapy.humira is indicated for reducing signs and symptoms and inducing clinical r